Donate Toggle Menu

Personalised treatment benefits kidney cancer patients

Personalised treatment plans may extend life expectancy for early-stage kidney cancer patients who have risk factors for worsening kidney disease, according to a new study published in the journal Radiology.

First-Line TKIs Less Effective in Non-Clear-Cell Renal Cell Carcinoma

According to a study that was published in Urologic Oncology, patients with metastatic non-clear-cell renal cell carcinoma (nccRCC) have worse outcomes from first-line therapy with tyrosine kinase inhibitors (TKIs) than patients with metastatic clear-cell RCC (ccRCC).

Imaging Advances in the Management of Kidney Cancer

New developments in cross-sectional imaging, including contrast-enhanced ultrasound, dual-energy computed tomography, multiparametric magnetic resonance imaging, single-photon emission computed tomography, and positron emission tomography, together with novel application of existing and novel radiotracers, have changed the landscape of renal mass characterization (ie, virtual biopsy) as well as the detection of metastatic disease, prognostication, and response assessment in patients with advanced kidney cancer.

Kidney Cancer Association Appoints Gretchen Vaughan as CEO

Kidney Cancer Association is pleased to announce it has recently appointed Gretchen Vaughan as the nonprofit’s new CEO. Vaughan brings more than 27 years of experience in advanced fundraising, management, sales and major market business development in the healthcare and financial service industries.

Ten-Year Outcomes of Renal Tumor Radio Frequency Ablation

According to a study that was published by the Journal of Urology, a total of 112 tumors in 106 patients were treated with radio frequency ablation. The median followup was 79 months (IQR 28.9-121.1) and mean ± SD tumor size was 2.5 ± 0.8 cm. Initial technical success was achieved in 97 percent of cases.

1 4 5 6 7

Media Contact

Email Radha Chitale with media inquiries. Please include your name, outlet, topic, deadline, and contact details.